Table 1.

Patient demographics

BlinatumomabTisagenlecleucel infusedTisagenlecleucel enrolled
N = 70N = 79N = 97
Age (years), median (range) 8.0 (<1-17.0) 11.0 (3.0-24.0) 11.0 (3-27) 
Male, n (%)* 47 (67.1) 45 (57.0) 54 (55.7) 
Geographic region, n (%)*    
 United States/Canada 22 (31.4) 44 (55.7) 56 (57.7) 
 European Union 48 (68.6) 28 (35.4) 32 (33.0) 
 Other 0 (0.0) 7 (8.9) 9 (9.3) 
Karnofsky/Lansky performance status ≥50%, n (%)* 70 (100.0) 79 (100.0) 79 (81.4) 
Previous alloSCT, n (%) 40 (57.1) 48 (60.8) 58 (59.7) 
Previous relapses, n (%)    
 0 2 (2.9) 6 (7.6) 8 (8.3) 
 1 31 (44.3) 21 (26.6) 29 (29.9) 
 2 29 (41.4) 17 (21.5) 18 (18.6) 
 ≥3 8 (11.4) 35 (44.3) 42 (43.3) 
Months since last relapse, median (range)* 2.9 (0.4-49.8) 3.5 (1.5-13.8) NA 
Bone marrow blast count ≥50%, n (%)* 52 (74.3) 54 (68.4) 70 (72.2) 
Refractory to last treatment, n (%) 39 (56) 77 (53.8) 94 (55) 
BlinatumomabTisagenlecleucel infusedTisagenlecleucel enrolled
N = 70N = 79N = 97
Age (years), median (range) 8.0 (<1-17.0) 11.0 (3.0-24.0) 11.0 (3-27) 
Male, n (%)* 47 (67.1) 45 (57.0) 54 (55.7) 
Geographic region, n (%)*    
 United States/Canada 22 (31.4) 44 (55.7) 56 (57.7) 
 European Union 48 (68.6) 28 (35.4) 32 (33.0) 
 Other 0 (0.0) 7 (8.9) 9 (9.3) 
Karnofsky/Lansky performance status ≥50%, n (%)* 70 (100.0) 79 (100.0) 79 (81.4) 
Previous alloSCT, n (%) 40 (57.1) 48 (60.8) 58 (59.7) 
Previous relapses, n (%)    
 0 2 (2.9) 6 (7.6) 8 (8.3) 
 1 31 (44.3) 21 (26.6) 29 (29.9) 
 2 29 (41.4) 17 (21.5) 18 (18.6) 
 ≥3 8 (11.4) 35 (44.3) 42 (43.3) 
Months since last relapse, median (range)* 2.9 (0.4-49.8) 3.5 (1.5-13.8) NA 
Bone marrow blast count ≥50%, n (%)* 52 (74.3) 54 (68.4) 70 (72.2) 
Refractory to last treatment, n (%) 39 (56) 77 (53.8) 94 (55) 

Variables describe patients at baseline of their respective trials.

At enrollment, blinatumomab patients had >25% bone marrow blasts; tisagenlecleucel patients had ≥5% lymphoblasts in bone marrow.

*

Not considered in adjustment because of unavailability of patient-level data within the blinatumomab dataset published in Gore et al.20 

or Create an Account

Close Modal
Close Modal